Halozyme Therapeutics (HALO) : results from Phase 1b Trial of PEGPH20

Halozyme Therapeutics announces positive opinion from CHMP on Roche's (RHHBY) Herceptin SC for European Approval (HALO) 7.13 +0.76 : Co announced that Roche (RHHBY) received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the subcutaneous formulation of Herceptin (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with HER2-positive breast cancer in Europe.

  

** daily **

** monthly **